Trump's Executive Order Targets Middlemen in Drug Pricing to Lower Costs

President Donald Trump signed a new executive order aimed at aligning U.S. drug prices with those of other countries by removing private-sector middlemen from the system. While the move caused a drop in stocks, it promises significant changes for the pharmaceutical industry.

President Donald Trump took a significant step to address rising drug costs in the U.S. on Monday by signing an executive order aimed at removing private-sector middlemen from the pricing process. This move is designed to align American drug prices with those in other countries, which pay considerably less for the same medications.

The new order seeks to directly connect pharmaceutical companies with U.S. consumers, bypassing the intermediaries who often inflate costs through hidden discounts and administrative fees. In a press conference, Trump stated, "We’re going to cut out the middlemen and facilitate the direct sale of drugs at the most favored nation price, directly to the American citizen."

The United States currently pays about three times more for prescription drugs than other nations. Under the executive order, pharmaceutical companies will be required to charge similar prices in both the U.S. and Europe. Additionally, the U.S. Department of Health will establish a system that allows patients to purchase medications directly from manufacturers, potentially lowering costs significantly.

Pharmaceutical Stocks See Volatility

The announcement sent shockwaves through the stock market. Shares of major pharmacy benefit managers (PBMs) — CVS Health, UnitedHealth Group, and Cigna — all saw declines, with CVS down 5%, UnitedHealth dropping 0.5%, and Cigna falling 6%. These companies manage prescription drug plans for millions of Americans through their pharmacy benefit manager subsidiaries, Caremark, Optum Rx, and Express Scripts, respectively.

PBMs have long been under scrutiny for their role in driving up drug prices. The Federal Trade Commission (FTC) has already applied regulatory pressure on these firms, particularly over their pricing practices for insulin. Critics argue that PBMs’ hidden fees and rebates contribute to the high costs of medications by obscuring the true price consumers pay.

Pharmaceutical Industry Responds

While the pharmaceutical industry has placed much of the blame on PBMs for inflated prices, industry representatives stress that the real issue lies with drug manufacturers. Greg Lopes, Vice President of Public Affairs at the Pharmaceutical Care Management Association, argued that PBMs are essential in counteracting the pricing power of drug companies.

CVS, in a statement, welcomed Trump’s focus on drug pricing and emphasized its willingness to work with the administration to make medications more affordable. The company also pointed out that its negotiations with drugmakers have resulted in significantly lower costs for prescription drugs, especially for Medicare beneficiaries, compared to prices set by the government.

Cigna and UnitedHealth did not respond immediately to requests for comment.

Challenges in Implementation

Despite the potential benefits, analysts caution that implementing these changes may face significant hurdles. One of the biggest challenges is the U.S. reliance on employer-sponsored health plans, which could complicate the direct purchase of medications by consumers. Julie Utterback, an analyst at Morningstar, noted that PBMs provide bundled services to their clients, and companies could raise the costs of other services to offset the impact of lower drug prices.

Utterback also pointed out that UnitedHealth, which is more diversified than CVS and Cigna, saw less of a stock decline because its business model is not as heavily reliant on retail pharmacy operations. CVS, on the other hand, could face challenges from reduced prices on prescription medications.

The administration’s focus on lowering drug prices is not without controversy. While the move has been welcomed by consumers and some industry players, it is likely to face resistance in Congress and from stakeholders who fear it could disrupt existing business models.

Copied